AstraZeneca and Sanofi have been approved in China for the prevention of respiratory syncytial virus infection in infants with nisetizumab
多德德多w
发表于 2024-1-2 16:36:11
1382
0
0
On January 2nd, AstraZeneca and Sanofi jointly announced the long-acting monoclonal antibody Le Weichu& Reg; Nirsevimab has been officially approved for marketing by the National Medical Products Administration of China for the prevention of lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in newborns and infants. This medication is suitable for newborns and infants who are about to enter or are born during the first RSV infection season. Nisevizumab is expected to be launched in China during the RSV infection season of 2024-2025. AstraZeneca stated that Nisevizumab is the first officially approved respiratory syncytial virus infection prevention measure for newborns and infants in China.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- General Motors Q3 sold over 420000 vehicles in China, surpassing gasoline powered vehicles for the first time in new energy vehicles
- Has the 'fixed price' policy been effective? General Motors' sales in China increased by 14.3% month on month in the third quarter, and SAIC GM's orders for certain models were overstocked
- Hyatt Hotels and China Resources Land establish a joint venture for light asset expansion, continuing to expand into the Chinese market
- The Boston Science Harbor Base has been completed and opened, achieving "independent production" in China
- When will Apple AI be launched in China? Cook responds!
- Dialogue with Meng Pu, Chairman of Qualcomm China: Qualcomm has long-term accumulation in China and will adhere to the path of self-developed chips
- This US funded enterprise has clarified its confidence and direction for development in China through the CIIE
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- AbbVie Dual Anti Cancer New Drug Declares for Market in China
- A sharp drop of 87%! Maserati will only sell over 30 units in China in September! Has the 'Sports Car Queen' fallen from grace?
-
"영비릉: 2024회계연도 영업수입 동기대비 8% 감소"영비릉은 2024회계연도 재무제보를 발표했다.2024 회계연도 매출은 149억5500만 유로로 전년 동기 대비 8% 감소했습니다.이익은 31억 500만 유로입니다.이익률은 ...- 勇敢的树袋熊1
- 3 일전
- Up
- Down
- Reply
- Favorite
-
계면신문기자 장우발 4분기의 영업수입이 하락한후 텐센트음악은 다시 성장으로 돌아왔다. 11월 12일, 텐센트음악은 최신 재보를 발표했다.2024년 9월 30일까지 이 회사의 3분기 총수입은 70억 2천만 위안으로 전년 ...
- 勇敢的树袋熊1
- 그저께 15:27
- Up
- Down
- Reply
- Favorite
-
본사소식 (기자 원전새): 11월 14일, 다다그룹 (나스닥코드: DADA) 은 2024년 3분기 실적보고를 발표했다. 수치가 보여준데 따르면 고품질발전전략에 지속적으로 전념하고 사용자체험을 끊임없이 최적화하며 공급을 ...- 家养宠物繁殖
- 어제 15:21
- Up
- Down
- Reply
- Favorite
-
11월 12일 소식에 따르면 소식통에 따르면 아마존은 무료스트리밍서비스 Freevee를 페쇄하고 일부 종업원과 프로를 구독서비스 Prime Video로 이전할 계획이다. 올해 초 아마존이 내놓은 몇 편의 대형 드라마의 효 ...- 度素告
- 그저께 13:58
- Up
- Down
- Reply
- Favorite
